StockData
Replimune Group, Inc. logo

Replimune Group, Inc. (REPL) stock

REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.69−1.72 (-8.03%)

Close on Nov 17, 2026Market cap $1.87BP/E –Yield –

Replimune shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Replimune's shares outstanding was 105M at Sep 30, 2026. For fiscal 2026 it was 93M, up 15.2% from the year before. The highest annual figure on record is 93M in fiscal 2026.

Annual shares outstanding

PeriodPeriod endValueChange
FY2026Mar 31, 202693M+15.2%
FY2025Mar 31, 202581M+21.0%
FY2024Mar 31, 202467M+14.4%
FY2023Mar 31, 202358M+11.5%
FY2022Mar 31, 202252M+12.9%
FY2021Mar 31, 202146M+35.0%
FY2020Mar 31, 202034M+47.7%
FY2019Mar 31, 201923M+366.0%
FY2018Mar 31, 20185M+0.1%
FY2017Mar 31, 20175M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2027CQ3 2026Sep 30, 2026105M+14.4%
Q1 FY2027CQ2 2026Jun 30, 202697M+5.8%
Q4 FY2026CQ1 2026Mar 31, 202696M+5.1%
Q3 FY2026CQ4 2025Dec 31, 202592M+10.4%
Q2 FY2026CQ3 2025Sep 30, 202592M+17.0%
Q1 FY2026CQ2 2025Jun 30, 202592M+32.3%
Q4 FY2025CQ1 2025Mar 31, 202591M+36.3%
Q3 FY2025CQ4 2024Dec 31, 202483M+25.3%
Q2 FY2025CQ3 2024Sep 30, 202479M+18.0%
Q1 FY2025CQ2 2024Jun 30, 202469M+4.2%
Q4 FY2024CQ1 2024Mar 31, 202467M+1.0%
Q3 FY2024CQ4 2023Dec 31, 202367M+15.2%
Q2 FY2024CQ3 2023Sep 30, 202367M+21.6%
Q1 FY2024CQ2 2023Jun 30, 202366M+22.4%
Q4 FY2023CQ1 2023Mar 31, 202366M+25.6%
Q3 FY2023CQ4 2022Dec 31, 202258M+10.6%
Q2 FY2023CQ3 2022Sep 30, 202255M+5.2%
Q1 FY2023CQ2 2022Jun 30, 202254M+4.4%
Q4 FY2022CQ1 2022Mar 31, 202253M+1.6%
Q3 FY2022CQ4 2021Dec 31, 202152M+5.9%
Q2 FY2022CQ3 2021Sep 30, 202152M+18.3%
Q1 FY2022CQ2 2021Jun 30, 202152M+30.2%
Q4 FY2021CQ1 2021Mar 31, 202152M+33.1%
Q3 FY2021CQ4 2020Dec 31, 202049M+41.6%
Q2 FY2021CQ3 2020Sep 30, 202044M+39.0%
Q1 FY2021CQ2 2020Jun 30, 202040M+25.9%
Q4 FY2020CQ1 2020Mar 31, 202039M+23.3%
Q3 FY2020CQ4 2019Dec 31, 201935M+10.5%
Q2 FY2020CQ3 2019Sep 30, 201932M+28.9%
Q1 FY2020CQ2 2019Jun 30, 201932M+535.6%
Q4 FY2019CQ1 2019Mar 31, 201931M+532.2%
Q3 FY2019CQ4 2018Dec 31, 201832M+533.9%
Q2 FY2019CQ3 2018Sep 30, 201825M+393.6%
Q1 FY2019CQ2 2018Jun 30, 20185M+0.2%
Q4 FY2018CQ1 2018Mar 31, 20185M–
Q3 FY2018CQ4 2017Dec 31, 20175M–
Q2 FY2018CQ3 2017Sep 30, 20175M–
Q1 FY2018CQ2 2017Jun 30, 20175M–

More Replimune figures

See a number that looks wrong?